doi:10.3969/j.issn.1004-583X.2022.06.015

Abstract

CLC Number:

R459.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.06.015

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I6/556

References 33

[1]	王华, 梁延春. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
[2]	Vaduganathan M, Claggett BL, Desai AS, et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF[J]. J Am Coll Cardiol, 2020, 75(3): 245-254. doi: S0735-1097(19)38299-3 pmid: 31726194
[3]	Ayalasomayajula S, Langenickel T, Pal P, et al. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): A novel angiotensin receptor-neprilysin inhibitor[J]. Clin Pharmacokinet, 2017, 56(12): 1461-1478. doi: 10.1007/s40262-017-0543-3 pmid: 28417439
[4]	Di Lullo L, Ronco C, Bellasi A, et al. Neprilysin inhibition and chronic kidney disease[J]. G Ital Nefrol, 2017, 34(5): 102-112.
[5]	Fu S, Xu Z, Lin B, et al. Effects of sacubitril-valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis[J]. Front Med, 2021, 8: 657067. doi: 10.3389/fmed.2021.657067 URL
[6]	张聪, 郭艳红, 杨自君, 等. 沙库巴曲/缬沙坦在心力衰竭腹膜透析患者中的应用[J]. 肾脏病与透析肾移植杂志, 2022, 31(1):26-32.
[7]	胡楠, 朱颖辉, 吕楠, 等. 沙库巴曲缬沙坦在维持性血液透析患者中治疗慢性心功能不全的有效性和安全性[J]. 中国血液净化, 2022, 21(1):10-14.
[8]	Tien KJ, Lin ZZ, Chio CC, et al. Epidemiology and mortality of new-onset diabetes after dialysis: Tiwan national cohort study[J]. Diabetes Care, 2013, 36(10): 3027-3032. doi: 10.2337/dc12-2148 URL
[9]	Jakher H, Chang TI, Tan M, et al. Canagliflozin review-safety and efficacy profile in patients with T2DM[J]. Diabetes Metab Syndr Obes, 2019, 12: 209. doi: 10.2147/DMSO.S184437 URL
[10]	Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24): 2295-2306. doi: 10.1056/NEJMoa1811744 URL
[11]	Wheeler DC, James J, Patel D, et al. SGLT2 inhibitors: Slowing of chronic kidney disease progression in type 2 diabetes[J]. Diabetes Ther, 2020, 11(12): 2757-2774. doi: 10.1007/s13300-020-00930-x URL
[12]	Mcmurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008. doi: 10.1056/NEJMoa1911303 URL
[13]	Guthrie R. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. Postgrad Med, 2018, 130(2): 149-153. doi: 10.1080/00325481.2018.1423852 pmid: 29297732
[14]	杨顺昱, 江戈, 杨兰, 等. 达格列净治疗糖尿病合并慢性心力衰竭的临床研究[J]. 新医学, 2021, 52(12):956-961.
[15]	吕晨燕, 姜得悦, 高迎, 等. 服用达格列净的2型糖尿病合并慢性心力衰竭患者左心室舒张功能改变的观察[J]. 中国糖尿病杂志, 2020, 28(3):190-192.
[16]	Silver SA, Harel Z, Perl J. Practical considerations when prescribing icodextrin: A narrative review[J]. Am J Nephrol, 2014, 39(6): 515-527. doi: 10.1159/000363417 URL
[17]	Cho Y, Johnson DW, Badve S, et al. Impact of icodextrin on clinical outcomes in peritoneal dialysis: A systematic review of randomized controlled trials[J]. Nephrol Dial Transplant, 2013, 28(7): 1899-1907. doi: 10.1093/ndt/gft050 URL
[18]	阳晓, 余学清. 艾考糊精透析液对腹膜透析患者腹膜功能、容量负荷及代谢的影响[J]. 中华肾脏病杂志, 2008, 24(2):142-145.
[19]	Wang IK, Lin CL, Yen TH, et al. Icodextrin reduces the risk of congestive heart failure in peritoneal dialysis patients[J]. Pharmacoepidemiol Drug Saf, 2018, 27(4): 447-452. doi: 10.1002/pds.4412 pmid: 29490427
[20]	Wolfson M, Piraino B, Hamburger RJ, et al. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis[J]. Am J Kidney Dis, 2002, 40(5): 1055-1065. pmid: 12407652
[21]	Paniagua R, Ventura MD, Avila-Díaz M, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients[J]. Perit Dial Int, 2009, 29(4): 422-432. doi: 10.1177/089686080902900409 URL
[22]	Zhang S, Wang Z. Effect of recombinant human brain natriuretic peptide (rhBNP) versus nitroglycerin in patients with heart failure: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2016, 95(44):e4757. doi: 10.1097/MD.0000000000004757 URL
[23]	Elkayam U, Akhter MW, Singh H, et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure[J]. Am J Cardiol, 2004, 93(2): 237-240. pmid: 14715359
[24]	张勇. 重组人脑利钠肽对心力衰竭患者心功能、炎症指标、血浆N末端脑钠肽原、尿量的影响[J]. 中国实用医药, 2022, 17(2):111-113.
[25]	李月. 新活素治疗维持性透析并心力衰竭患者的疗效观察[J]. 医学信息, 2014, (12):160-160, 161.
[26]	吕勇. 中医药在腹膜透析治疗中的临床应用概论[J]. 现代中医药, 2022, 42(1):22-27.
[27]	束永兵, 张志辉. 真武汤加减治疗老年腹膜透析合并慢性心力衰竭患者的临床疗效[J]. 中国老年学杂志, 2021, 41(14):2934-2936.
[28]	刘茜, 周华, 瞿惠燕, 等. 周华教授基于“从肾治心”理论分阶段治疗慢性心力衰竭经验[J]. 中西医结合心脑血管病杂志, 2022, 20(3):563-565.
[29]	向洪术, 黄益麒. 中药穴位贴敷联合重组人脑利钠肽治疗腹膜透析合并慢性心力衰竭的临床观察[J]. 中国中医药科技, 2022, 29(2):231-233.
[30]	Löfman I, Szummer K, Dahlström U, et al. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction[J]. Eur J Heart Fail, 2017, 19(12): 1606-1614. doi: 10.1002/ejhf.821 pmid: 28371075
[31]	Antlanger M, Aschauer S, Kopecky C, et al. Heart failure with preserved and reduced ejection fraction in hemodialysis patients: Prevalence, disease prediction and prognosis[J]. Kidney Blood Press Res, 2017, 42(1): 165-176. doi: 10.1159/000473868 URL
[32]	Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective[J]. Circ Res, 2019, 124(11): 1598-1617. doi: 10.1161/CIRCRESAHA.119.313572 pmid: 31120821
[33]	Solomon SD, Mcmurray JJ, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17): 1609-1620. doi: 10.1056/NEJMoa1908655 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 33

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2023, 38(12): 1150-1152.
[2]	Gong Zhiqing, Lu Dongmei, Xing Guangqun. The predictive and prognostic potential of serum parathyroid hormone combined with the nutritional status score on peritoneal dialysis catheter-related peritonitis [J]. Clinical Focus, 2023, 38(11): 991-995.
[3]	. [J]. Clinical Focus, 2023, 38(11): 1038-1041.
[4]	Li Hengnan, Huang Yan, Zhao Yajuan, Hu Guicai. Correlation between serum CTRP5 and left ventricular diastolic dysfunction in patients with continuous ambulatory peritoneal dialysis and its diagnostic value [J]. Clinical Focus, 2023, 38(4): 324-329.
[5]	Tao Yang, Pan Qingquan, Li Yan. Evaluation of hemoperfusion and continuous renal replacement therapy in paraquat poisoning patients complicated with MODS [J]. Clinical Focus, 2023, 38(4): 330-334.
[6]	Zhang Hongtao, Wang Zhikui. Renal anemia in patients with maintenance peritoneal dialysis and Related Factors: A single-center study [J]. Clinical Focus, 2022, 37(12): 1099-1103.
[7]	Cheng Huidong, Si Bolin, Hua Qin, He Jianqiang, Gui Lanlan. Efficacy comparison between pull and surgical technique for removal of peritoneal dialysis catheter [J]. Clinical Focus, 2021, 36(12): 1097-1101.
[8]	. [J]. Clinical Focus, 2021, 36(12): 1136-1138.
[9]	Shang Qihang, Chen Huaqian. Relationship between eosinophil levels and carotid atherosclerosis in maintenance hemodialysis patients [J]. Clinical Focus, 2021, 36(1): 44-48.
[10]	Shi Youshan, Chen Tianhao. Pathogenic bacteria and etiological analysis of peritoneal dialysisassociated peritonitis in a single peritoneal dialysis center [J]. Clinical Focus, 2020, 35(11): 1010-1014.
[11]	Duan Hailing;Cui Xiangqin;Wang Zongbao;Liu Guanbin;Geng Mingliang. Clinical application of vitamin E combined with hemoperfusion in maintenance hemodialysis patients [J]. Clinical Focus, 2015, 30(11): 1288-1291.
[12]	Wei Qing;Liu Hong;Tang Rining;Liu Bicheng. Sevelamer on curative effect and endpoint events in hemodialysis patients--a meta analysis [J]. Clinical Focus, 2015, 30(9): 1008-1.0121e+007.
[13]	Jia Yanli;Wang Ying;Cheng Hao;Sun Yi. Level and influential factors of serum Klotho in maintenance hemodialysis patients [J]. Clinical Focus, 2015, 30(8): 928-931.
[14]	Xu Zhuoj ia;Zhan Cheng;Wang Kai. Identification and characterization of Staphylococcus epidermidis from hemodialysis patients with tunneled-cuffed central venous catheters and hemodialysis environment [J]. Clinical Focus, 2015, 30(3): 308-311.
[15]	. [J]. Clinical Focus, 2015, 30(3): 357-360.